In 2026 the global health landscape saw four major moves: the WHO lost the United States as a member, India cleared the way for semaglutide generic production, courts in the US and Europe intensified scrutiny of social‑media impact on youth, and India reviewed its progress toward eliminating malaria. These developments affect public‑health governance, drug affordability, child protection, and disease‑control targets – all core topics for UPSC aspirants.
Key Developments
- The United States formally withdrew from the WHO, citing funding concerns and sovereignty issues.
- India’s drug regulators granted licences to domestic manufacturers to produce generic versions of semaglutide, expanding the obesity‑treatment market in India.
- Judicial and legislative bodies in the United States and Europe began hearings on stricter, enforceable safeguards for children on social‑media platforms.
- India’s National Vector‑Borne Disease Control Programme released a mid‑term review of the malaria‑elimination drive, noting state‑level successes and persistent gaps.
Important Facts
• The US withdrawal became effective on 1 January 2026, removing its annual contribution of roughly US$400 million to the WHO budget.
• Two Indian firms received approval to manufacture semaglutide generics, potentially cutting prices by up to 70 % compared with imported brands.
• The European Parliament’s Digital Services Act amendment proposes mandatory age‑verification and content‑filtering tools for platforms with users under 18.
• As of 2025, India reported a 45 % reduction in malaria cases since 2015, but eight high‑burden states still account for > 70 % of cases.
Exam Relevance
These events intersect with multiple GS papers. The US exit raises questions on public health governance, international cooperation, and funding mechanisms (GS1). The generic semaglutide case illustrates patent law, drug pricing, and access to medicines – topics in GS3 and GS4. Social‑media regulation touches on child rights, digital governance, and the balance between freedom of expression and protection (GS2, GS4). Finally, malaria elimination aligns with India’s health‑security goals, vector‑control policies, and the Sustainable Development Goals (GS1).
Way Forward
- India should leverage the generic semaglutide rollout to build domestic R&D capacity and ensure price transparency.
- The government must engage with the WHO to fill the funding gap left by the US, possibly by increasing contributions from emerging economies.
- Policymakers need to draft clear, enforceable guidelines for social‑media platforms, focusing on age‑verification, data‑privacy, and harmful‑content algorithms.
- For malaria, targeted interventions in high‑burden states, strengthened surveillance, and community‑based vector control are essential to meet the 2030 elimination target.